These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 12799613)

  • 1. Central muscarinic acetylcholine receptor availability in patients treated with clozapine.
    Raedler TJ; Knable MB; Jones DW; Urbina RA; Egan MF; Weinberger DR
    Neuropsychopharmacology; 2003 Aug; 28(8):1531-7. PubMed ID: 12799613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the in-vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine.
    Raedler TJ
    Int J Neuropsychopharmacol; 2007 Apr; 10(2):275-80. PubMed ID: 16945161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia.
    Raedler TJ; Knable MB; Jones DW; Urbina RA; Gorey JG; Lee KS; Egan MF; Coppola R; Weinberger DR
    Am J Psychiatry; 2003 Jan; 160(1):118-27. PubMed ID: 12505810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia.
    Raedler TJ; Knable MB; Jones DW; Lafargue T; Urbina RA; Egan MF; Pickar D; Weinberger DR
    Neuropsychopharmacology; 2000 Jul; 23(1):56-68. PubMed ID: 10869886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients.
    Farde L; Nordström AL; Nyberg S; Halldin C; Sedvall G
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():67-9. PubMed ID: 7961577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.
    Nordström AL; Farde L; Nyberg S; Karlsson P; Halldin C; Sedvall G
    Am J Psychiatry; 1995 Oct; 152(10):1444-9. PubMed ID: 7573582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457.
    Talvik M; Nordström AL; Nyberg S; Olsson H; Halldin C; Farde L
    Am J Psychiatry; 2001 Jun; 158(6):926-30. PubMed ID: 11384901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients.
    Trichard C; Paillère-Martinot ML; Attar-Levy D; Recassens C; Monnet F; Martinot JL
    Am J Psychiatry; 1998 Apr; 155(4):505-8. PubMed ID: 9545996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150.
    Travis MJ; Busatto GF; Pilowsky LS; Mulligan R; Acton PD; Gacinovic S; Mertens J; Terrière D; Costa DC; Ell PJ; Kerwin RW
    Br J Psychiatry; 1998 Sep; 173():236-41. PubMed ID: 9926100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
    Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
    la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
    J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
    Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
    Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients.
    Farde L; Nordström AL
    Br J Psychiatry Suppl; 1992 May; (17):30-3. PubMed ID: 1358126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects.
    Broich K; Grünwald F; Kasper S; Klemm E; Biersack HJ; Möller HJ
    Pharmacopsychiatry; 1998 Sep; 31(5):159-62. PubMed ID: 9832346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.
    Pickar D; Su TP; Weinberger DR; Coppola R; Malhotra AK; Knable MB; Lee KS; Gorey J; Bartko JJ; Breier A; Hsiao J
    Am J Psychiatry; 1996 Dec; 153(12):1571-8. PubMed ID: 8942453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.